PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients

  • days left to enroll
  • participants needed
  • sponsor
    PhytoHealth Corporation
Updated on 14 July 2022


The objective of this study is to assess the efficacy of weekly PG2 regimen as a complementary treatment for patients with recurrent unresectable (local or regional) or metastatic breast cancer who experienced moderate to severe fatigue while receiving chemotherapies.


The objective of this study is to assess the efficacy of weekly PG2 regimen as a complementary treatment for patients with recurrent unresectable (local or regional) or metastatic breast cancer who experienced moderate to severe fatigue while receiving chemotherapies. The primary endpoint is to examine whether PG2, compar ed with placebo, can successfully reduce patients' fatigue (observed via prorated area under the curve [AUC] for the Brief Fatigue Inventory [BFI] scores) when primed with PG2 for 8 weeks during their chemotherapy. The other efficacy endpoints including th e time course change of patient reported BFI, fatigue improvement response rate (fatigue improvement response is defined as those with at least 10% reduction from baseline in the total BFI scores) after 8 weeks, self perceived improvement, hematological improvement, health related quality of life, and safety profiles will also be assessed between treatment arms and compared with the baseline.

Condition Cancer-related Fatigue
Treatment PG2 Lyo. Injection 500mg, Placebo 0.9% normal saline
Clinical Study IdentifierNCT05440227
SponsorPhytoHealth Corporation
Last Modified on14 July 2022


Yes No Not Sure

Inclusion Criteria

Women aged ≥ 20 years
ECOG performance score ≤ 2
Locally advanced, recurrent or metastatic, histologically documented breast cancer who is currently undergoing infusional chemotherapy regimen
Presence of moderate to severe cancer related fatigue prior to randomization as defined by at least two records of usual fatigue score ≥ 4 on the numeric scale (0 -10), which must be ≥ 14 days apart
Laboratory values obtained prior to randomization
Hgb ≥ 10 g/dL (patients must not be transfused ≤ 14 days to meet this criterion)
Creatinine ≤ 1.2 x ULN
AST (SGOT) or ALT (SGPT) ≤1.5 x ULN (or ≤5.0 x ULN for patients with liver metastases)
Pain under controlled of score ≤ 4 on the numeric scale (0 -10)
Life expectancy ≥ 3 months
Ability to complete patient questionnaires alone or with assistance
Negative pregnancy test done ≤ 14 days prior to randomization, for women of childbearing potential only, and willing to take efficient contraceptives procedures to avoid pregnancy throughout the study period
Willing to provide written informed consent and agree to follow the study requirements

Exclusion Criteria

Known brain metastasis or primary CNS malignancy
Has known psychiatric or substance abuse disorders
Malnutrition, active infection, uncontrolled thyroid disorder, uncontrollable hypertension or diabetes mellitus, significant pulmonary disease and cardiovascular disease
Currently using any other pharmacologic agents
Subject who is unwilling to receive transfusions when, at the investigator's discretion, it is required to control her anemia
Other medical conditions that necessitate chronic systemic use of steroids (e.g. use of prednisolone > 10 mg daily or equivalent steroids fore more than 2 weeks)
≤ 4 weeks from major surgery to randomization, including any procedure that requires general anesthetics
Pain requiring opioid pain medication, however, over the counter analgesics such as acetaminophen or ibuprofen are allowed
Use of monoamine oxidase inhibitors (MAOI) (such as Moclobemide)
Planning to start or complete any type of cancer therapy during the 8 weeks course of the study, once randomized on the study
Use of any over the counter herbal/dietary supplement marketed for fatigue or energy
Known history of hypersensitivity to Astragalus products
Currently participating another interventional study or planning to join one in the upcoming 8 weeks after randomization
Currently breast feeding
With any other serious disease considered by the investigator not in the condition to enter into the trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note